CROMOLYN SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cromolyn Sodium, and when can generic versions of Cromolyn Sodium launch?
Cromolyn Sodium is a drug marketed by Ailex Pharms Llc, Genera Pharms, Micro Labs Ltd India, Rising, Akorn, Apotex Inc, Sandoz, Actavis Mid Atlantic, Bausch, Eugia Pharma, Hikma, Micro Labs, Roxane, Teva Pharms, Virtus, Watson Labs, Wockhardt Bio Ag, Bausch And Lomb, Hh And P, and Perrigo. and is included in twenty-two NDAs.
The generic ingredient in CROMOLYN SODIUM is cromolyn sodium. There are ten drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the cromolyn sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cromolyn Sodium
A generic version of CROMOLYN SODIUM was approved as cromolyn sodium by SANDOZ on June 16th, 1999.
Summary for CROMOLYN SODIUM
US Patents: | 0 |
Applicants: | 20 |
NDAs: | 22 |
Finished Product Suppliers / Packagers: | 15 |
Raw Ingredient (Bulk) Api Vendors: | 98 |
Clinical Trials: | 23 |
Patent Applications: | 6,417 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in CROMOLYN SODIUM? | CROMOLYN SODIUM excipients list |
DailyMed Link: | CROMOLYN SODIUM at DailyMed |
Recent Clinical Trials for CROMOLYN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Texas Tech University Health Sciences Center, El Paso | Phase 3 |
Adli Karadsheh, MD, MS | Phase 3 |
MedAvante | Phase 2 |
Pharmacology for CROMOLYN SODIUM
Drug Class | Mast Cell Stabilizer |
Physiological Effect | Decreased Histamine Release |